Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation-Reference-Cited by-同舟云学术

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Published:2018-06-28 Issue:1 Volume:11 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Chen Robert W.,Palmer Joycelynne M.,Tomassetti Sarah,Popplewell Leslie L.,Alluin Jessica,Chomchan Pritsana,Nademanee Auayporn P.,Siddiqi Tanya,Tsai Ni-Chun,Chen Lu,Zuo Fay,Abary Rosemarie,Cai Ji-lian,Herrera Alex F.,Rossi John J.,Rosen Steven T.,Forman Stephen J.,Kwak Larry W.,Holmberg Leona A.

Funder

Millennium Pharmaceuticals

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-018-0631-3.pdf

Reference23 articles.

1. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–18. https://www.ncbi.nlm.nih.gov/pubmed/9166827 .

2. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.

3. Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard N, Ribrag V, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16:587–93.

4. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–62.

5. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of agricultural carbon emissions in China based on a GA-ELM model;Frontiers in Energy Research;2023-10-13

2. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen;Acta Haematologica;2023-09-14

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Mantle cell lymphoma management trends and novel agents: where are we going?;Therapeutic Advances in Hematology;2022-01

5. Advances in the assessment of minimal residual disease in mantle cell lymphoma;Journal of Hematology & Oncology;2020-09-24